An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1063-1069

  Michon, J M ^a   Hartmann, O ^b   Bouffet, E ^c   Meresse, V ^d   Coze, C ^e   Rubie, H ^f   Bordigoni, P ^g   Cattiaux, E ^d   Ward, N ^h   Bernard, J L ^e   Lemerle, J ^b   Zucker, J M ^a   Philip, T ^c  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Laboratoires AMGEN   (France)

^e TIMONE HOSPITAL   (France)

^f CHU PURPAN   (France)

^g CHU NANCY BRABOIS   (France)

^h AMGEN LTD   (United Kingdom)

Author keywords

Chemotherapy; Children; Dose intensity; Filgrastim; Infection; Neuroblastoma; Neutropenia

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FEVER; FILGRASTIM; HUMANS; INFANT; MALE; NEUROBLASTOMA; NEUTROPENIA; TREATMENT OUTCOME; VINCRISTINE;

EID: 7144262406     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00061-6     Document Type: Article

References (20)

1. Pinkerton C.R. Where next with therapy in advanced neuroblastoma? Br J Cancer. 61:1990;351-353.
2. Shafford A.E., Rogers D.W., Pritchard J. Advanced neuroblastoma improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM26. J Clin Oncol. 2:1984;742-747.
3. Bernard JL, Philip T, Zucker JM, et al. Sequential cisplatin VM26 and vincristine-cyclophosphamide-doxorubicin in metastatic neuroblastoma. An effective alternating non-cross resistant regimen? J Clin Oncol 1987, 5, 1952-1959.
4. Pinkerton CR, Zucker JM, Hartmann O, et al. Short duration, high dose intensity induction chemotherapy in advanced neuroblastoma. Is there any therapeutic gain? Br J Cancer 1990, 62, 319-323.
5. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE 1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991, 9, 1037-1044.
6. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988, 318, 1414-1422.
7. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325, 164-170.
8. Trillet-Lenoir V, Grenn J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A, 319-324.
9. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988, 6, 1874-1881.
10. Michon J, Philip T, Hartmann O, et al. NB87. A new protocol using an alternating non cross resistant induction regimen and two different modalities of massive consolidation chemotherapy with autologous purged bone marrow rescue in the treatment of metastatic neuroblastoma in children over one year of age. In Dicke K, Spitzer G, eds. Autologous Transplantation. 5th Symposium on Autologous Transplantation. The University of Texas MD Anderson Cancer Center, 1989, pp. 529-541.
11. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987, 56, 809-813.
12. Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocytemacrophage colony stimulating factor reduces hematologic toxicity and widens clinical applicability of high dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990, 8, 768-778.
13. Takada M, Fukuoka M, Ariyoshi Y, et al. The use of granulocyte colony stimulating factor to shorten the interval between cycles of mytomycin C, vindesine and cisplatin chemotherapy in non small cell lung cancer. Cancer Chemother Pharmacol 1992, 31, 182-186.
14. Welte K, Reiter A, Mempel K, et al. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996, 87, 3143-3150.
15. Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of granulocyte colony stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989, 320, 1574-1580.
16. Stute N, Santana VM, Rodman JH, et al. Pharmacokinetics of subcutaneous recombinant granulocyte colony-stimulating factor in children. Blood 1992, 79, 2849-2854.
17. Furman W.L., Crist W.M. Biology and clinical applications of hemopoietins in pediatric practice. Pediatrics. 90:1992;716-728.
18. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997, 336, 1781-1787.
19. Cheung N.K., Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression free survival in metastatic neuroblastoma. J Clin Oncol. 9:1991;1050-1058.
20. Pearson AD, Craft AW, Pinkerton CR, et al. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 1992, 28A, 1654-1659.